<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>QUESTRAN- cholestyramineÂ powder, for suspensionÂ </strong><br>Par Pharmaceutical Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="inv-22ca657d-948c-42b0-b880-7fe3898ca497"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">QUESTRAN <span class="Sup">Â®</span> (Cholestyramine for Oral Suspension USP), the chloride salt of a basic anion exchange resin, a <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> lowering agent, is intended for oral administration. Cholestyramine resin is quite hydrophilic, but insoluble in water. The cholestyramine resin in QUESTRAN is not absorbed from the digestive tract. Four grams of anhydrous cholestyramine resin is contained in 9 grams of QUESTRAN powder. Four grams of anhydrous cholestyramine resin is contained in 5 grams of QUESTRAN LIGHT. It is represented by the following structural formula:</p>
<div class="Figure">
<a name="ID0EALAC"></a><img alt="this is the structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=362ddd91-a63f-4ec6-841a-75785dd208c8&amp;name=structure.jpg">
</div>
<p><span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> is probably the sole precursor of bile acids. During normal digestion, bile acids are secreted into the intestines. A major portion of the bile acids is absorbed from the intestinal tract and returned to the liver via the enterohepatic circulation. Only very small amounts of bile acids are found in normal serum.</p>
<p>QUESTRAN resin adsorbs and combines with the bile acids in the intestine to form an insoluble complex which is excreted in the feces. This results in a partial removal of bile acids from the enterohepatic circulation by preventing their absorption.</p>
<p>The increased fecal loss of bile acids due to QUESTRAN administration leads to an increased oxidation of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> to bile acids, a decrease in beta lipoprotein or low density lipoprotein plasma levels and a decrease in serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels. Although in man, QUESTRAN produces an increase in hepatic synthesis of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, plasma <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span>.</p>
<p>In patients with partial biliary obstruction, the reduction of serum bile acid levels by QUESTRAN reduces excess bile acids deposited in the dermal tissue with resultant decrease in <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.</p>
<p>QUESTRAN (Cholestyramine for Oral Suspension USP) contains the following inactive ingredients: acacia, citric acid, D&amp;C Yellow No. 10, FD&amp;C Yellow No. 6, flavor (natural and artificial Orange), polysorbate 80, propylene glycol alginate and sucrose. QUESTRAN LIGHT (Cholestyramine for Oral Suspension USP, Light) contains the following inactive ingredients: aspartame, citric acid, colloidal silicon dioxide, D&amp;C Yellow No. 10, FD&amp;C Red No. 40, flavor (natural and artificial Orange), maltodextrin, propylene glycol alginate and xanthan gum.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="inv-edcea376-dcba-4476-b977-b58831f13be7"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> is probably the sole precursor of bile acids. During normal digestion, bile acids are secreted into the intestines. A major portion of the bile acids is absorbed from the intestinal tract and returned to the liver via the enterohepatic circulation. Only very small amounts of bile acids are found in normal serum.</p>
<p>Cholestyramine resin adsorbs and combines with the bile acids in the intestine to form an insoluble complex which is excreted in the feces. This results in a partial removal of bile acids from the enterohepatic circulation by preventing their absorption.</p>
<p>The increased fecal loss of bile acids due to Cholestyramine administration leads to an increased oxidation of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> to bile acids, a decrease in beta lipoprotein or low density lipoprotein plasma levels and a decrease in serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels. Although in man, Cholestyramine produces an increase in hepatic synthesis of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, plasma <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span>.</p>
<p>In patients with partial biliary obstruction, the reduction of serum bile acid levels by Cholestyramine reduces excess bile acids deposited in the dermal tissue with resultant decrease in <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="inv-6fdc5902-1917-4069-8adb-147103985ab7"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">1) QUESTRAN (Cholestyramine for Oral Suspension USP), is indicated as adjunctive therapy to diet for the reduction of elevated serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> in patients with primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span> (elevated low density lipoprotein [LDL] <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>) who do not respond adequately to diet. QUESTRAN may be useful to lower LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> in patients who also have <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>, but it is not indicated where <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> is the abnormality of most concern.</p>
<p>Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>. Treatment should begin and continue with dietary therapy specific for the type of <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipoproteinemia</span> determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight.</p>
<p>Prior to initiating therapy with QUESTRAN, secondary causes of <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span> (e.g., poorly controlled <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span>, dysproteinemias, obstructive liver disease, other drug therapy, <span class="product-label-link" type="condition" conceptid="4218106" conceptname="Alcoholism">alcoholism</span>), should be excluded, and a lipid profile performed to assess Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, HDL-C, and triglycerides (TG). For individuals with TG less than 400 mg/dL (&lt;4.5 mmol/L), LDL-C can be estimated using the following equation:</p>
<p>LDL-C = Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> â€“ [(TG/5) + HDL-C]</p>
<p>For TG levels &gt;400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases QUESTRAN may not be indicated.</p>
<p>Serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> reduction should occur during the first month of QUESTRAN therapy. The therapy should be continued to sustain <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> reduction. If adequate <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> reduction is not attained, increasing the dosage of QUESTRAN or adding other lipid-lowering agents in combination with QUESTRAN should be considered.</p>
<p>Since the goal of treatment is to lower LDL-C, the NCEP <span class="Sup">4</span> recommends that LDL-C levels be used to initiate and assess treatment response. If LDL-C levels are not available then Total-C alone may be used to monitor long-term therapy. A lipoprotein analysis (including LDL-C determination) should be carried out once a year. The NCEP treatment guidelines are summarized below. </p>
<table width="100%">
<col width="21%">
<col width="24%">
<col width="29%">
<col width="26%">
<tfoot>
<tr class="First"><td class="Botrule" align="left" colspan="4" valign="top">*Coronary heart disease or <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span> (including symptomatic <span class="product-label-link" type="condition" conceptid="4153380" conceptname="Disorder of carotid artery">carotid artery disease</span>).</td></tr>
<tr class="Last"><td class="Botrule" align="left" colspan="4" valign="top">**Other risk factors for coronary heart disease (CHD) include: age (males â‰¥45 years; females â‰¥55 years or <span class="product-label-link" type="condition" conceptid="198715" conceptname="Premature menopause">premature menopause</span> without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>; confirmed HDL-C &lt;35 mg/dL (&lt;0.91 mmol/L); and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus. Subtract one risk factor if HDL-C is â‰¥60 mg/dL (â‰¥1.6 mmol/L).</td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule"><p class="First">Â  </p></td>
<td class="Botrule Toprule"><p class="First"> Â  </p></td>
<td class="Botrule Toprule"><p class="First"> Â  </p></td>
<td class="Botrule Rrule Toprule"><p class="First"> LDL-<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> mg/dL (mmol/L) </p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First"> Definite Atherosclerotic Disease* </p></td>
<td class="Botrule" align="center"><p class="First"> Two or More Other Risk Factors** </p></td>
<td class="Botrule" align="center"><p class="First"> Â   Initiation   Level </p></td>
<td class="Botrule Rrule" align="center"><p class="First"> Â   Goal </p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First"> NO </p></td>
<td class="Botrule" align="center"><p class="First"> NO </p></td>
<td class="Botrule" align="center"><p class="First"> â‰¥190   (â‰¥4.9) </p></td>
<td class="Botrule Rrule" align="center"><p class="First"> &lt;160   (&lt;4.1) </p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First"> NO </p></td>
<td class="Botrule" align="center"><p class="First"> YES </p></td>
<td class="Botrule" align="center"><p class="First"> â‰¥160   (â‰¥4.1) </p></td>
<td class="Botrule Rrule" align="center"><p class="First"> &lt;130   (&lt;3.4) </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center"><p class="First"> YES </p></td>
<td class="Botrule" align="center"><p class="First"> YES or NO </p></td>
<td class="Botrule" align="center"><p class="First"> â‰¥130   (â‰¥3.4) </p></td>
<td class="Botrule Rrule" align="center"><p class="First"> â‰¤100   (â‰¤2.6) </p></td>
</tr>
</tbody>
</table>
<p>1) QUESTRAN monotherapy has been demonstrated to retard the rate of progression <span class="Sup">2,3</span> and increase the rate of regression<span class="Sup">3</span> of <span class="product-label-link" type="condition" conceptid="4194618" conceptname="Coronary artery atheroma">coronary atherosclerosis</span>.</p>
<p>2) QUESTRAN is indicated for the relief of <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> associated with partial biliary obstruction. QUESTRAN for oral suspension has been shown to have a variable effect on serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> in these patients. Patients with <span class="product-label-link" type="condition" conceptid="4135822" conceptname="Primary biliary cirrhosis">primary biliary cirrhosis</span> may exhibit an elevated <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> as part of their disease.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="inv-b88f8f83-b82c-4bc8-8d71-ce7605e3bd53"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">QUESTRAN is contraindicated in patients with complete biliary obstruction where bile is not secreted into the intestine and in those individuals who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of its components.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="inv-07cd2e0d-fdd4-40ac-bad9-06d6e152407a"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Bold">PHENYLKETONURICS: CHOLESTYRAMINE for ORAL SUSPENSION USP, LIGHT CONTAINS 14.0 mg PHENYLALANINE PER 5 GRAM DOSE. </span></p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="inv-fae3ed89-4c41-4f18-a1be-381c68a9e9bd"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="inv-9379f27c-747d-4fdf-be26-1724887c297b"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">Chronic use of QUESTRAN may be associated with increased <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">bleeding tendency</span> due to <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span> associated with <span class="product-label-link" type="condition" conceptid="435781" conceptname="Vitamin K deficiency">Vitamin K deficiency</span>. This will usually respond promptly to parenteral Vitamin K1 and recurrences can be prevented by oral administration of Vitamin K1. Reduction of serum or red cell folate has been reported over long term administration of QUESTRAN. Supplementation with folic acid should be considered in these cases.</p>
<p>There is a possibility that prolonged use of QUESTRAN, since it is a chloride form of anion exchange resin, may produce <span class="product-label-link" type="condition" conceptid="4108257" conceptname="Metabolic acidosis, NAG, acidifying salts">hyperchloremic acidosis</span>. This would especially be true in younger and smaller patients where the relative dosage may be higher. Caution should also be exercised in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> or <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span>, and in patients receiving concomitant spironolactone.</p>
<p>QUESTRAN may produce or worsen pre-existing <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. The dosage should be increased gradually in patients to minimize the risk of developing <span class="product-label-link" type="condition" conceptid="4258683" conceptname="Fecal impaction">fecal impaction</span>. In patients with pre-existing <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, the starting dose should be 1 packet or 1 scoop once daily for 5â€“7 days, increasing to twice daily with monitoring of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> and of serum lipoproteins, at least twice, 4â€“6 weeks apart. Increased fluid intake and fiber intake should be encouraged to alleviate <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> and a stool softener may occasionally be indicated. If the initial dose is well tolerated, the dose may be increased as needed by one dose/day (at monthly intervals) with periodic monitoring of serum lipoproteins. If <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> worsens or the desired therapeutic response is not achieved at one to six doses/day, combination therapy or alternate therapy should be considered. Particular effort should be made to avoid <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> in patients with symptomatic <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>. <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> associated with QUESTRAN may aggravate <span class="product-label-link" type="condition" conceptid="194382" conceptname="External hemorrhoids">hemorrhoids</span>.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="inv-1ac713af-4544-4b49-ab9c-e61b395f694b"></a><a name="section-6.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Inform your physician if you are pregnant or plan to become pregnant or are breastfeeding. Drink plenty of fluids and mix each 9 gram dose of QUESTRAN Powder in at least 2 to 6 ounces of fluid. Mix each 5 gram dose of QUESTRAN LIGHT in at least 2 to 6 ounces of fluid before taking. Sipping or holding the resin suspension in the mouth for <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span> may lead to changes in the surface of the teeth resulting in discoloration, erosion of enamel or decay; good oral hygiene should be maintained.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="inv-08cdfe81-31b3-481b-bb2c-ed067dab4b38"></a><a name="section-6.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels should be determined frequently during the first few months of therapy and periodically thereafter. Serum triglyceride levels should be measured periodically to detect whether significant changes have occurred.</p>
<p>The LRC-CPPT showed a dose-related increase in serum triglycerides of 10.7%â€“17.1% in the cholestyramine-treated group, compared with an increase of 7.9%â€“11.7% in the placebo group. Based on the mean values and adjusting for the placebo group, the cholestyramine-treated group showed an increase of 5% over pre-entry levels the first year of the study and an increase of 4.3% the seventh year.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="inv-50a53a9e-522b-4bcf-8f4e-1835965fd539"></a><a name="section-6.4"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">QUESTRAN (Cholestyramine for Oral Suspension USP) may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic), or propranolol (basic), as well as tetracycline, penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis. Interference with the absorption of oral phosphate supplements has been observed with another positively-charged bile acid sequestrant. QUESTRAN may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation. The discontinuance of QUESTRAN could pose a hazard to health if a potentially toxic drug such as digitalis has been titrated to a maintenance level while the patient was taking QUESTRAN.</p>
<p>Because cholestyramine binds bile acids, QUESTRAN may interfere with normal fat digestion and absorption and thus may prevent absorption of fat-soluble vitamins such as A, D, E and K. When QUESTRAN is given for long periods of time, concomitant supplementation with water-miscible (or parenteral) forms of fat-soluble vitamins should be considered.</p>
<p>Â </p>
<p>SINCE QUESTRAN MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST ONE HOUR <span class="Underline">BEFORE </span>OR 4 TO 6 HOURS <span class="Underline">AFTER </span>QUESTRAN (OR AT AS GREAT AN INTERVAL AS POSSIBLE) TO AVOID IMPEDING THEIR ABSORPTION. </p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="inv-995d9160-6333-4251-85ac-73784c10b7fd"></a><a name="section-6.5"></a><p></p>
<h2>Carcinogenesis and Mutagenesis and Impairment of Fertility</h2>
<p class="First">In studies conducted in rats in which cholestyramine resin was used as a tool to investigate the role of various intestinal factors, such as fat, bile salts and microbial flora, in the development of intestinal tumors induced by potent carcinogens, the incidence of such tumors was observed to be greater in cholestyramine resin-treated rats than in control rats.</p>
<p>The relevance of this laboratory observation from studies in rats to the clinical use of QUESTRAN is not known. In the LRC-CPPT study referred to above, the total incidence of fatal and nonfatal neoplasms was similar in both treatment groups. When the many different categories of tumors are examined, various alimentary system cancers were somewhat more prevalent in the cholestyramine group. The small numbers and the multiple categories prevent conclusions from being drawn. However, in view of the fact that cholestyramine resin is confined to the GI tract and not absorbed, and in light of the animal experiments referred to above, a six-year post-trial follow-up of the LRC-CPPT <span class="Sup">5</span> patient population has been completed (a total of 13.4 years of in-trial plus post-trial follow-up) and revealed no significant difference in the incidence of cause-specific mortality or cancer morbidity between cholestyramine and placebo treated patients. </p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="inv-f5e74363-b82d-4126-bbad-323c3b8adb71"></a><a name="section-6.6"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-095b3aa8-6e27-4552-860f-2f063694d7e3"></a><a name="section-6.6.1"></a><p></p>
<h3><span class="Bold">Pregnancy Category C</span></h3>
<p class="First">There are no adequate and well controlled studies in pregnant women. The use of QUESTRAN in pregnancy or lactation or by women of childbearing age requires that the potential benefits of drug therapy be weighed against the possible hazards to the mother and child. QUESTRAN is not absorbed systemically, however, it is known to interfere with absorption of fat-soluble vitamins; accordingly, regular prenatal supplementation may not be adequate (see <span class="Bold">PRECAUTIONS: Drug Interactions</span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="inv-b693bba9-7052-4b37-afd0-7aabbdbef7b7"></a><a name="section-6.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Caution should be exercised when QUESTRAN is administered to a nursing mother. The possible lack of proper vitamin absorption described in the <span class="Bold">â€œPregnancyâ€? </span>section </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="inv-3c9c5d83-6b9d-4ff3-8a56-ba8f849a81e4"></a><a name="section-6.8"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Although an optimal dosage schedule has not been established, standard texts <span class="Sup">(6,7)</span> list a usual pediatric dose of 240 mg/kg/day of anhydrous cholestyramine resin in two to three divided doses, normally not to exceed 8 gm/day with dose titration based on response and tolerance. </p>
<p>In calculating pediatric dosages, 44.4 mg of anhydrous choleystramine resin are contained in 100 mg of QUESTRAN powder and 80 mg of anhydrous cholestyramine resin are contained in 100 mg of QUESTRAN LIGHT.</p>
<p>The effects of long-term administration, as well as its effect in maintaining lowered <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels in pediatric patients, are unknown. (Also see <span class="Bold">ADVERSE REACTIONS</span>.) </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="inv-71fca5f3-9640-4789-afe5-128fd5408421"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The most common adverse reaction is <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. When used as a <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>-lowering agent predisposing factors for most complaints of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> are high dose and increased age (more than 60 years old). Most instances of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> are mild, transient, and controlled with conventional therapy. Some patients require a temporary decrease in dosage or discontinuation of therapy.</p>
<p>Less Frequent Adverse Reactions: <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">Abdominal discomfort</span> and/or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, and <span class="product-label-link" type="condition" conceptid="200146" conceptname="Pancreatic steatorrhea">steatorrhea</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> tendencies due to <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span> (<span class="product-label-link" type="condition" conceptid="435781" conceptname="Vitamin K deficiency">Vitamin K deficiency</span>) as well as Vitamin A (one case of <span class="product-label-link" type="condition" conceptid="374037" conceptname="Night blindness">night blindness</span> reported) and D deficiencies, <span class="product-label-link" type="condition" conceptid="4108257" conceptname="Metabolic acidosis, NAG, acidifying salts">hyperchloremic acidosis</span> in children, <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and irritation of the skin, tongue and perianal area. Rare reports of <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, including two <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>, have been reported in pediatric patients.</p>
<p>Occasional calcified material has been observed in the biliary tree, including calcification of the gallbladder, in patients to whom QUESTRAN has been given. However, this may be a manifestation of the liver disease and not drug related.</p>
<p>One patient experienced <span class="product-label-link" type="condition" conceptid="4291807" conceptname="Biliary colic">biliary colic</span> on each of three occasions on which he took QUESTRAN. One patient diagnosed as acute abdominal symptom complex was found to have a â€œpasty massâ€? in the transverse colon on x-ray.</p>
<p>Other events (not necessarily drug related) reported in patients taking QUESTRAN include:</p>
<p>Â </p>
<p>Gastrointestinalâ€”GI-<span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span>, <span class="product-label-link" type="condition" conceptid="4148536" conceptname="Dark stools">black stools</span>, <span class="product-label-link" type="condition" conceptid="4198840" conceptname="Bleeding hemorrhoids">hemorrhoidal bleeding</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> from known <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccups</span>, <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> attack, sour taste, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="76458" conceptname="Rectal pain">rectal pain</span>, <span class="product-label-link" type="condition" conceptid="4109737" conceptname="Diverticulitis">diverticulitis</span>.</p>
<p>Laboratory test changesâ€”Liver function abnormalities.</p>
<p>Hematologicâ€”Prolonged <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span></p>
<p>Hypersensitivityâ€”<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>.</p>
<p>Musculoskeletalâ€”<span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Backache</span>, muscle and <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pains</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>.</p>
<p>Neurologicâ€”<span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, femoral <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">nerve pain</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>.</p>
<p>Eyeâ€”<span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">Uveitis</span>.</p>
<p>Renalâ€”<span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, burnt odor to urine, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>.</p>
<p>Miscellaneousâ€”<span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight loss</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="4237753" conceptname="Increased libido">increased libido</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">swollen glands</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, dental <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="133228" conceptname="Dental caries">dental caries</span>, erosion of tooth enamel, <span class="product-label-link" type="condition" conceptid="45757361" conceptname="Mottled teeth">tooth discoloration</span>.</p>
<p>Â </p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="inv-f34bd16a-3274-4293-a856-2f9ae5dd110e"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Overdosage with QUESTRAN has been reported in a patient taking 150% of the maximum recommended daily dosage for a period of several weeks. No ill effects were reported. Should an overdosage occur, the chief potential harm would be obstruction of the gastrointestinal tract. The location of such potential obstruction, the degree of obstruction, and the presence or absence of normal gut motility would determine treatment.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="inv-2bf64391-772f-40ff-81f1-ca06f90c3eb1"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended starting adult dose for all QUESTRAN powdered products (QUESTRAN Powder and QUESTRAN Light) is one packet or one level scoopful once or twice a day. The recommended maintenance dose for all QUESTRAN powdered products is 2 to 4 packets or scoopfuls daily (8-16 grams anhydrous cholestyramine resin) divided into two doses. Four grams of anhydrous cholestyramine resin is contained in each measured dose of QUESTRAN as follows:</p>
<p>Â </p>
<table width="100%">
<col width="59%">
<col width="41%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule"><p class="First">QUESTRAN Powder</p></td>
<td class="Botrule Toprule"><p class="First"> 9 grams  </p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule"><p class="First">QUESTRAN Light </p></td>
<td class="Botrule"><p class="First"> 5 grams </p></td>
</tr>
</tbody>
</table>
<p>It is recommended that increases in dose be gradual with periodic assessment of lipid/lipoprotein levels at intervals of not less than 4 weeks. The maximum recommended daily dose is six packets or scoopfuls of QUESTRAN (24 grams of anhydrous cholestyramine resin). The suggested time of administration is at mealtime but may be modified to avoid interference with absorption of other medications. Although the recommended dosing schedule is twice daily, QUESTRAN may be administered in 1â€“6 doses per day.</p>
<p><span class="Bold">QUESTRAN should not be taken in its dry form. Always mix QUESTRAN with water or other fluids before ingesting. See Preparation Instructions.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-c4cacb81-0436-4b67-83eb-8a77fbaf9d9e"></a><a name="section-9.1"></a><p></p>
<h2>Concomitant Therapy </h2>
<p class="First">Preliminary evidence suggests that the lipid-lowering effects of QUESTRAN on total and LDL-<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> are enhanced when combined with a HMG-CoA reductase inhibitor, e.g., pravastatin, lovastatin, simvastatin, and fluvastatin. Additive effects on LDL-<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> are also seen with combined nicotinic acid/QUESTRAN therapy. See the <span class="Bold">Drug Interactions </span>subsection of the <span class="Bold">PRECAUTIONS </span>section for recommendations on administering concomitant therapy. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-4ae31dba-8a05-4db0-80e0-d9ba456ee79a"></a><a name="section-9.2"></a><p></p>
<h2>PREPARATION</h2>
<p class="First">The color of QUESTRAN may vary somewhat from batch to batch but this variation does not affect the performance of the product. Place the contents of one single-dose packet or one level scoopful of QUESTRAN in a glass or cup. Add an amount of water or other noncarbonated beverage of your choice depending on the product being used:</p>
<table width="100%">
<col width="60%">
<col width="40%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule"><p class="First"><span class="Bold">Â </span>  Product Formula </p></td>
<td class="Botrule Toprule"><p class="First"><span class="Bold">Amount of Water or other</span>   Non-Carbonated Liquid </p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"> QUESTRAN Powder</p></td>
<td class="Botrule"><p class="First"> 2-6 ounces per dose </p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule"><p class="First"> QUESTRAN LIGHT</p></td>
<td class="Botrule"><p class="First"> 2-6 ounces per dose  </p></td>
</tr>
</tbody>
</table>
<p>Stir to a uniform consistency and drink.</p>
<p>QUESTRAN may also be mixed with highly fluid soups or pulpy fruits with a high moisture content such as applesauce or crushed pineapple.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="inv-44011475-e95b-4681-a3bb-c6840ded1225"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">QUESTRAN <span class="Sup">Â®</span> Powder (Cholestyramine for Oral Suspension USP) is available in cans containing 378 grams and in cartons of sixty 9 gram packets. Four grams of anhydrous cholestyramine resin are contained in 9 grams of QUESTRAN Powder. The 378 g can includes a 15 cc scoop. The scoop is not interchangeable with scoops from other products.</p>
<table width="100%">
<col width="47%">
<col width="53%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule"><p class="First"><span class="Bold">NDC 49884-936-66</span></p></td>
<td class="Botrule Toprule"><p class="First"><span class="Bold">Can, 378 g</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule"><p class="First"><span class="Bold">NDC 49884-936-65</span></p></td>
<td class="Botrule"><p class="First"><span class="Bold">Carton of 60, 9 g packets</span></p></td>
</tr>
</tbody>
</table>
<p>QUESTRAN <span class="Sup">Â®</span> LIGHT (Cholestyramine for Oral Suspension USP), Light is available in cans containing 210 grams and in cartons of sixty 5 gram packets. Four grams of anhydrous cholestyramine resin are contained in 5 grams of QUESTRAN LIGHT. The 210 g can includes a 9 cc scoop. The scoop is not interchangeable with scoops from other products.</p>
<table width="100%">
<col width="47%">
<col width="53%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule"><p class="First"><span class="Bold">NDC 49884-937-67 </span></p></td>
<td class="Botrule Toprule"><p class="First"><span class="Bold">Can, 210 g </span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule"><p class="First"><span class="Bold">NDC 49884-937-65 </span></p></td>
<td class="Botrule"><p class="First"><span class="Bold">Carton of 60, 5 g packets </span></p></td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="inv-e343611a-29b1-4257-a2b9-6c85538a1c65"></a><a name="section-10.1"></a><p></p>
<h2>Storage</h2>
<p class="First">Store between 20Âº-25ÂºC (68Âº-77ÂºF). [See USP Controlled Room Temperature]. Excursions permitted to 15Âº-30ÂºC (59Âº-86ÂºF).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="inv-31bda3e7-5a87-4d91-b8a7-bf6b5e71136d"></a><a name="section-11"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First">In a large, placebo-controlled, multi-clinic study, LRC-CPPT 1, hypercholesterolemic subjects treated with QUESTRAN had mean reductions in total and low-density lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (LDL-C) which exceeded those for diet and placebo treatment by 7.2% and 10.4%, respectively. Over the seven-year study period the QUESTRAN group experienced a 19% reduction (relative to the incidence in the placebo group) in the combined rate of coronary heart disease <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> plus non-fatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (cumulative incidences of 7% QUESTRAN and 8.6% placebo). The subjects included in the study were men aged 35 - 59 with serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels above 265 mg/dL and no previous history of heart disease. It is not clear to what extent these findings can be extrapolated to females and other segments of the hypercholesterolemic population. (See also PRECAUTIONS: Carcinogenesis, Mutagenesis, Impairment of Fertility.)</p>
<p>Two controlled clinical trials have examined the effects of QUESTRAN monotherapy upon coronary atherosclerotic lesions using coronary arteriography. In the NHLBI Type II Coronary Intervention Trial 2, 116 patients (80% male) with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> (CAD) documented by arteriography were randomized to QUESTRAN or placebo for five years of treatment. Final study arteriography revealed progression of <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> in 49% of placebo patients compared to 32% of the QUESTRAN group (p&lt;0.05).</p>
<p>In the St. Thomas <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">Atherosclerosis</span> Regression Study (STARS) 3, 90 hypercholesterolemic men with CAD were randomized to three blinded treatments: usual care, lipid-lowering diet, and lipid-lowering diet plus QUESTRAN. After 36 months, follow-up coronary arteriography revealed progression of disease in 46% of usual care patients, 15% of patients on lipid-lowering diet and 12% of those receiving diet plus QUESTRAN (p&lt;0.02). The mean absolute width of coronary segments decreased in the usual care group, increased slightly (0.003mm) in the diet group and increased by 0.103mm in the diet plus QUESTRAN group (p&lt;0.05). Thus in these randomized controlled clinical trials using coronary arteriography, QUESTRAN monotherapy has been demonstrated to slow progression 2,3 and promote regression3 of atherosclerotic lesions in the coronary arteries of patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>.</p>
<p>The effect of intensive lipid-lowering therapy on <span class="product-label-link" type="condition" conceptid="4194618" conceptname="Coronary artery atheroma">coronary atherosclerosis</span> has been assessed by arteriography in hyperlipidemic patients. In these randomized, controlled clinical trials, patients were treated for two to four years by either conventional measures (diet, placebo, or in some cases low dose resin), or intensive combination therapy using diet plus colestipol (an anion exchange resin with a mechanism of action and an effect on serum lipids similar to that of QUESTRAN and QUESTRAN LIGHT) plus either nicotinic acid or lovastatin. When compared to conventional measures, intensive lipid-lowering combination therapy significantly reduced the frequency of progression and increased the frequency of regression of coronary atherosclerotic lesions in patients with or at risk for <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="inv-00d0f23a-6c26-401a-b9fa-b03a6af86b26"></a><a name="section-12"></a><p></p>
<h1>REFERENCES</h1>
<dl>
<dt>â€¢</dt>
<dd>The Lipid Research Clinics Coronary Primary Prevention Trial Results: (I) Reduction in Incidence of Coronary Heart Disease; (II) The Relationship of Reduction in Incidence of Coronary Heart Disease to <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> Lowering. JAMA 1984; 251:351-374. </dd>
<dt>â€¢</dt>
<dd>Brensike JF, Levy RI, Kelsey SF, et al. Effects of therapy with cholestyramine on progression of coronary <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">arteriosclerosis</span>: results of the NHLBI type II coronary intervention study. Circulation 1984;69:313-24. </dd>
<dt>â€¢</dt>
<dd>Watts, GF, Lewis B, Brunt JNH, Lewis ES, et al. Effects on <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">Atherosclerosis</span> Regression Study (STARS). Lancet 1992;339:563-69. </dd>
<dt>â€¢</dt>
<dd>National <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> in Adults (Adult Treatment Panel II). Circulation 1994 Mar; 89(3):1333-445. </dd>
<dt>â€¢</dt>
<dd>The Lipid Research Clinics Investigators. The Lipid Research Clinics Coronary Primary Prevention Trial: Results of 6 Years of Post-Trial Follow-up. Arch Intern Med 1992; 152:1399-1410. </dd>
<dt>â€¢</dt>
<dd>Behrman RE et al (eds): Nelson, Textbook of Pediatrics, ed 15. Philadelphia, PA, WB Saunders Company, 1996. </dd>
<dt>â€¢</dt>
<dd>Takemoto CK et al (eds): Pediatric Dosage Handbook, ed 3. Cleveland/Akron, OH, Lexi-Comp, Inc., 1996-1997. </dd>
</dl>
<p class="First">Distributed by:</p>
<p><span class="Bold">PAR PHARMACEUTICAL COMPANIES, INC.</span></p>
<p>Spring Valley, NY 10977</p>
<table width="100%">
<col width="50%">
<col width="50%">
<tbody class="Headless"><tr class="First Last">
<td class="Botrule Rrule Toprule"><p class="First"> Revised: 05/06</p></td>
<td class="Botrule Toprule"><p class="First"> OS466-65-1-02 </p></td>
</tr></tbody>
</table>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="inv-d76f6cfc-16b6-40a1-972f-884d964feb6b"></a><a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL, 378 GRAM CAN </h1>
<div class="Figure">
<a name="ID0EAXAE"></a><img alt="this is the regular can" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=362ddd91-a63f-4ec6-841a-75785dd208c8&amp;name=Questran_%20Reg_Can.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="inv-1a6d48b9-f5ba-4320-aba3-338b3c733d34"></a><a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL, CARTON 60 PACKETS PER CARTON</h1>
<div class="Figure">
<a name="ID0EVXAE"></a><img alt="this is the regular carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=362ddd91-a63f-4ec6-841a-75785dd208c8&amp;name=Questran_Carton_Reg.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="inv-6997b7b7-8708-44f8-896d-7a095155a43b"></a><a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL, 9 GRAM PACKET</h1>
<div class="Figure">
<a name="ID0EKYAE"></a><img alt="this is the regular pouch" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=362ddd91-a63f-4ec6-841a-75785dd208c8&amp;name=Questran_Reg_Pouch.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="inv-0f7d014d-6412-43ab-867b-3d8bc47fd834"></a><a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL, 210 GRAM CAN</h1>
<div class="Figure">
<a name="ID0E6YAE"></a><img alt="this is the light can" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=362ddd91-a63f-4ec6-841a-75785dd208c8&amp;name=Questran%20Light%20Can.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="inv-68ef6362-1f89-4a43-ae51-8c46745cddaf"></a><a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL, CARTON 60 PACKETS PER CARTON</h1>
<div class="Figure">
<a name="ID0EWZAE"></a><img alt="this is the light carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=362ddd91-a63f-4ec6-841a-75785dd208c8&amp;name=Questran%20Carton%20Light.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="inv-3e5ac4ba-c473-4b2c-8c68-386f7468fd90"></a><a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL, 5 GRAM PACKET</h1>
<div class="Figure">
<a name="ID0EN1AE"></a><img alt="This is the light pouch" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=362ddd91-a63f-4ec6-841a-75785dd208c8&amp;name=Questran%20Light%20Pouch.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>QUESTRANÂ 		
					</strong><br><span class="contentTableReg">cholestyramine powder, for suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49884-936</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CHOLESTYRAMINE</strong> (CHOLESTYRAMINE) </td>
<td class="formItem">CHOLESTYRAMINE</td>
<td class="formItem">4Â g Â inÂ 9Â g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ACACIA</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL ALGINATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS CITRIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">Â Â Â Â </td>
<td class="formLabel">Score</td>
<td class="formItem">Â Â Â Â </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">ORANGE</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49884-936-65</td>
<td class="formItem">60  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49884-936-64</td>
<td class="formItem">9 g in 1 PACKET; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:49884-936-66</td>
<td class="formItem">378 g in 1 CAN; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA077204</td>
<td class="formItem">09/15/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>QUESTRANÂ 		
					</strong><br><span class="contentTableReg">cholestyramine powder, for suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49884-937</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CHOLESTYRAMINE</strong> (CHOLESTYRAMINE) </td>
<td class="formItem">CHOLESTYRAMINE</td>
<td class="formItem">4Â g Â inÂ 5Â g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ACACIA</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL ALGINATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS CITRIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">Â Â Â Â </td>
<td class="formLabel">Score</td>
<td class="formItem">Â Â Â Â </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">ORANGE</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49884-937-65</td>
<td class="formItem">60  in 1 CARTON</td>
<td class="formItem">07/24/2003</td>
<td class="formItem">11/30/2016</td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49884-937-63</td>
<td class="formItem">5 g in 1 PACKET; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:49884-937-67</td>
<td class="formItem">210 g in 1 CAN; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA077203</td>
<td class="formItem">07/24/2003</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Par Pharmaceutical Inc.
							(092733690)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>Par Pharmaceutical Inc. (092733690)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Par Pharmaceutical Inc.</td>
<td class="formItem"></td>
<td class="formItem">092733690</td>
<td class="formItem">MANUFACTURE(49884-936, 49884-937)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>9e23b628-9a42-4cb7-aa2d-98e010469987</div>
<div>Set id: 362ddd91-a63f-4ec6-841a-75785dd208c8</div>
<div>Version: 5</div>
<div>Effective Time: 20150106</div>
</div>
</div>Â <div class="DistributorName">Par Pharmaceutical Inc.</div></p>
</body></html>
